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 Abstract 
Network-based computational method, with the emphasis on biomolecular 
interactions and biological data integration, has succeeded in drug development and 
created new directions, such as drug repositioning and drug combination. Drug 
repositioning, that is finding new uses for existing drugs to treat more patients, offers 
time, cost and efficiency benefits in drug development, especially when in silico 
techniques are used. microRNAs (miRNAs) play important roles in multiple 
biological processes and have attracted much scientific attention recently. Moreover, 
cumulative studies demonstrate that the mature miRNAs as well as their precursors 
can be targeted by small molecular drugs. At the same time, human diseases result 
from the disordered interplay of tissue- and cell lineage-specific processes. However, 
few computational researches predict drug-disease potential relationships based on 
miRNA data and tissue specificity. Therefore, based on miRNA data and the tissue 
specificity of diseases, we propose a new method named as miTS to predict the 
potential treatments for diseases. Firstly, based on miRNAs data, target genes and 
information of FDA (Food and Drug Administration) approved drugs, we evaluate the 
relationships between miRNAs and drugs in the tissue-specific PPI (protein-protein) 
network. Then, we construct a tripartite network: drug-miRNA-disease Finally, we 
obtain the potential drug-disease associations based on the tripartite network. In this 
paper, we take breast cancer as case study and focus on the top-30 predicted drugs. 25 
of them (83.3%) are found having known connections with breast cancer in CTD 
(Comparative Toxicogenomics Database) benchmark and the other 5 drugs are 
 potential drugs for breast cancer. We further evaluate the 5 newly predicted drugs 
from clinical records, literature mining, KEGG pathways enrichment analysis and 
overlapping genes between enriched pathways. For each of the 5 new drugs, strongly 
supported evidences can be found in three or more aspects. In particular, Regorafenib 
(DB08896) has 15 overlapping KEGG pathways with breast cancer and their p-values 
are all very small. In addition, whether in the literature curation or clinical validation, 
Regorafenib has a strong correlation with breast cancer. All the facts show that 
Regorafenib is likely to be a truly effective drug, worthy of our further study. It 
further follows that our method miTS is effective and practical for predicting new 
drug indications, which will provide potential values for treatments of complex 
diseases. 
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Introduction 
The identification of therapeutic approaches for the treatment of cancer is an arduous, 
costly, and often inefficient process. By conservative estimates, it now takes over 15 
years and $800 million to $1 billion to bring a new drug to market 1 . Drug 
repositioning, which is the discovery of new indications for existing drugs, is an 
increasingly attractive mode of therapeutic discovery. A repositioned drug does not 
need the initial six to nine years required for the development of new drugs, but 
instead goes directly to preclinical testing and clinical trials, thus reducing risk and 
costs2. Repositioning drugs has been implemented in several ways. One of the 
well-known examples is sildenafil citrate, which was repositioned from a 
 hypertension drug to a therapy for erectile dysfunction3. Drugs treat diseases by 
targeting the proteins related to the phenotypes arising from the disease. However, 
drug development does not accurately follow the “one gene, one drug, one disease” 
principle, which has been challenged in many cases4  and the traditional drug 
repositioning methods by accident makes it hard to satisfy medical needs by 
successfully repositioning a large number of existing drugs. Computational methods 
are able to solve this question by high-level integration of available biological data 
and elucidation of unknown mechanisms.  
In recent years, systems biology continues to make important progress to solve 
fundamental problems in biology and leading to practical applications in medicine 
and drug discovery5. Network-based computational systems biology emphasizes the 
interactions among biomolecules and highlights the network concept. Typically, a 
network comprises a set of nodes and edges, and is described by graph theory in a 
mathematical manner6. A node can be a biological molecule, for example, gene, RNA, 
protein, metabolite, and pathway. A node can also be at the phenotype level such as 
disease and drug. An edge can represent the complex interaction between two nodes 
such as protein-protein interaction, drug-disease therapeutic relationship, drug-protein 
target relationship, and so on. The accumulation of different high-throughput biology 
data, such as gene expression data, miRNA expression data and drug-target data, has 
made the reconstruction of biomolecular and cellular networks possible. Cheng et al. 
built a bipartite graph composed of the approved drugs and proteins linked by drug 
target binary associations, and relied on a supervised network-based inference method 
 to predict drug-target interactions7. Chen et al. constructed a general heterogeneous 
network which comprised drugs and proteins linked by protein-protein sequence 
similarity, drug-drug chemical similarity, and the known drug-target interaction8. Yeh 
et al.9 developed a network flow approach for identifying potential target proteins, 
which have a strong influence on disease genes in the context of biomolecular 
networks. The biomolecular networks are weighted by degree of co-expression of 
interacting protein pair. 
More recently, many studies have demonstrated that drugs can regulate microRNA 
(miRNAs) expression and mature miRNAs as well as their precursors can be targeted 
by small molecular drugs10,11,12,13. For example, Miravirsen (SPC3649) is the first 
miRNA-targeted drug in clinical trials, which can successfully inhibit miR-122 
expression that is required by hepatitis C virus replication14. The expression levels of 
32 miRNAs (significant up-regulation of 22 miRNAs and down-regulation of 10 
miRNAs) were changed after the treatment of trichostatin A in human breast cancer 
cell lines 15 . miRNAs are non-coding small RNAs (∼23 nucleotides) that 
downregulate gene expression at the post transcriptional level by inhibiting translation 
or initiating mRNA degradation and are dysregulated in most of human cancers16. 
Increasingly evidences have demonstrated that miRNAs play significant roles in many 
important biological processes, such as cell growth17, cellular signaling18, tissue 
development19 and disease process20. Although only approximately 2000 miRNAs 
exist in humans, they regulate 30% of all genes. miRNAs have been identified to play 
a crucial role in various human disease, especially in cancers. Therefore, targeting 
 miRNAs with drugs will provide a new type of therapy for complex diseases21 and a 
new direction for drug repositioning. However, few computational researches predict 
drug-disease relationships based on miRNA data. Moreover, many genes with 
tissue-specific expression and function are expected to underlie many human 
diseases22,23. 
Therefore, in this study, we propose a new method based on miRNA data and tissue 
specificity of diseases, named as miTS, to predict potential drugs for diseases. The 
framework of miTS is shown in Figure 1. Firstly, we download miRNA expression 
data of diseases from TCGA24, miRNA-target gene relationship data from three 
experimentally validated databases: miRecords25, miRTarbase26 and TarBase27, and 
the drug-target gene data from Drugbank28 and KEGG29. Secondly, we select 
differentially expressed miRNAs of diseases based on a threshold and preprocess the 
target information of FDA approved drugs. Thirdly, we evaluate the relationships 
between miRNAs and drugs in the tissue-specific PPI network. And then, we 
construct a tripartite network: drug-miRNA-disease. Finally, we obtain the potential 
drug-disease associations based on the tripartite network. In this paper, we take breast 
cancer as case study and evaluate the results from CTD benchmark, clinical records, 
literature mining, KEGG pathways enrichment analysis and overlapping genes 
between enriched pathways. In the top-30 drugs, we find 5 new drugs for breast 
cancer. In particular, Regorafenib (DB08896) has 15 overlapping KEGG pathways 
with breast cancer and their p-values are all very small. In addition, whether in the 
literature curation or clinical validation, Regorafenib has a strong correlation with  
  
Figure 1. The framework of our method miTS. (A) Data preparation: miRNA expression data of breast 
cancer got from TCGA, miRNA-target gene data got from miRecords, miRTarbase and TarBase, and 
drug-target gene data got from Drugbank and KEGG. (B) Data preprocessing: we use Z-score to obtain 
the differentially expressed miRNAs for diseases and preprocess the target information of drugs. (C) In 
the tissue-specific PPI network, the targets of drug and miRNA are mapped to the PPI network. Orange 
nodes represent the target genes of miRNAs. Purple nodes represent the target genes of drugs. Green 
nodes represent the background genes. (D) Based on the module distance algorithm, we construct a 
drug-miRNA-disease tripartite network, and then based on the tripartite network, we get potential drugs 
for diseases. dA,B represents the association score between a drug and a disease. 
 breast cancer. All the facts show that Regorafenib is likely to be a truly effective drug, 
worthy of our further study. 
Data and Method 
Data                                                            
Drug-target data: FDA-approved drugs of human and their corresponding targets are 
downloaded from KEGG database and Drugbank. We merge the two datasets and get 
1,732 drugs, 1,714 targets and 12,361 drug-target pairs.  
miRNA-target data: The target genes of miRNAs are downloaded from miRecords, 
miRTarbase, and TarBase databases. We merge the three datasets and get 340 
miRNAs, 2,028 targets and 3,652 miRNA-target pairs.  
miRNA-disease data: The miRNA-disease curated relationships are downloaded 
from HMDD (the Human microRNA Disease Database)30. HMDD presents more 
detailed and comprehensive annotations to the human miRNA-disease association 
data, including miRNA-disease association data from the evidence of genetics, 
epigenetics, circulating miRNAs, and miRNA-target interactions. Finally, we get 578 
miRNAs, 383 diseases and 6,448 miRNA-disease relationships.  
miRNA expression data: Taking breast cancer as case study, we download the 
miRNAs expression data related with breast cancer from TCGA and get a matrix of 
503 rows and 1,189 columns, row representing miRNA, column representing cancer 
sample, and the values in the matrix representing the RPKM (Reads Per Kilobase per 
Million mapped reads) for the miRNAs. We take the mean value of the RPKM values 
for 1,189 samples as the final value. 
 Disease-gene data: The genes related with breast cancer are downloaded from 
OMIM31 database.  
Tissue-specific PPI Interaction network: We download the mammary 
tissue-specific PPI network marked as “Top Edges” from GIANT (Genome-scale 
Integrated Analysis of gene Networks in Tissues) database32 (http://giant.princeton.edu/) 
(2017 version). GIANT proposes a tissue-specific benchmark to automatically 
up-weight datasets relevant to a tissue from a large data of different tissues and 
cell-types. Finally, we get 15,269 proteins and 883,071 protein-protein interactions. 
The weights on the edges are proportional to the relationships between nodes. In order 
to apply module distance algorithm33 to calculate the relationships between drugs and 
miRNAs, we use the Gaussian kernel 2we  to transfer protein-protein closeness w
to protein-protein distance w , as shown in formula (1).  
 
2' ww e                       (1) 
Method 
Screening differentially expressed miRNAs 
In order to obtain the differentially expressed miRNAs of breast cancer, we first filter 
the miRNAs expression data downloaded from TCGA. For a miRNA r , we use 
formula (2) to calculate its Z - score .  
                           mean( )( )
R - rZ - score =
r                            (2) 
Where R  is the RPKM value of miRNA r ; mean ( )r and ( )r represent mean 
value and standard deviation of r , respectively. Then we choose Z - score =1.645 
(p-value = 0.05) as threshold to screen differentially expressed miRNAs. Finally, we 
 get a total of 40 differentially expressed miRNAs of breast cancer (see Table 1). In 
Table 1, the miRNAs marked by “*” represent they have connections with breast 
cancer in HMDD. We find 34 of 40 (85%) differentially expressed miRNAs are 
related with breast cancer, which indicates that miRNAs associated with breast cancer 
tend to be highly expressed in breast cancer patients. Then, we choose the 34 miRNAs 
marked by “*” in Table 1 for further study. 
Table 1. Differentially expressed miRNAs of breast cancer 
miRNA name Z-score miRNA name Z-score miRNA name Z-score 
hsa-mir-21* 3.32 hsa-mir-375* 2.32 hsa-mir-23a* 1.91 
hsa-mir-22* 2.94 hsa-mir-101-1* 2.29 hsa-mir-199a-2* 1.90 
hsa-mir-10b* 2.93 hsa-mir-200c* 2.28 hsa-mir-126* 1.90 
hsa-mir-30a* 2.85 hsa-mir-25* 2.27 hsa-mir-100* 1.86 
hsa-mir-148a* 2.77 hsa-let-7a-3* 2.21 hsa-let-7c* 1.79 
hsa-mir-99b 2.73 hsa-let-7a-1* 2.21 hsa-mir-151 1.78 
hsa-mir-143* 2.73 hsa-mir-30d* 2.19 hsa-mir-199a-1* 1.73 
hsa-mir-182* 2.72 hsa-mir-92a-2* 2.18 hsa-mir-26a-2* 1.72 
hsa-let-7b* 2.61 hsa-let-7f-2* 2.12 hsa-mir-142 1.72 
hsa-mir-10a* 2.56 hsa-mir-93* 2.03 hsa-mir-29c* 1.70 
hsa-mir-103-1 2.50 hsa-mir-29a* 2.03 hsa-mir-181a-1* 1.69 
hsa-let-7a-2* 2.44 hsa-mir-28 2.00 hsa-mir-141* 1.66 
hsa-mir-30e 2.38 hsa-mir-199b* 1.98   
hsa-mir-183* 2.37 hsa-mir-203* 1.94   
The miRNAs marked by “*” represent they have relationship with breast cancer in HMDD. 
Construct drug-miRNA-disease tripartite network 
The relationship between a miRNA and a drug is derived by measuring the correlation 
between their target sets. Because miRNA target genes, drug target genes and 
protein-protein interaction (PPI) networks remain largely incomplete, we calculate the 
distance between two modules based on the shortest path in incomplete networks33. 
Figure 2 gives an example to calculate the distance between miRNA A and drug B in a 
weighted tissue-specific PPI network. As shown in Figure 2, miRNA A has three 
target genes, marked as a, b, c and drug B has four targets, marked as c, d, e, f. For the 
 node a, its distance to targets {c, d, e, f} of drug B are 0.8, 1.0, 1.1 and 1.9 
respectively, so its shortest distance to drug B is 0.8. In this way, we can obtain the 
distances between each node in gene set {a, b, c} and drug B, and the distances 
between each node in target set {c, d, e, f} and miRNA A, shown in Figure 2. Finally, 
the distance between miRNA A and drug B, ,ABd  , is equals to the sum of all the 
distances divided by the total number of nodes related to miRNA A and drug B. Here, 
the total number is 7. 
Figure 2. An example for calculating the distance between target set of miRNA A and target set of drug 
B. Orange and purple nodes represent genes related to miRNA A and drug B, respectively. Node c is a 
shared node, so it is marked by two colors. 
Through the above calculation process, we get 1,017 drugs, 25 miRNAs and 25,425 
drug-miRNA relationships. Combining the drug-miRNA relations with the 
 miRNA-breast cancer information, we construct a drug-miRNA-breast cancer 
tripartite network.  
Predicting potential drugs for breast cancer 
Based on the drug-miRNA-breast cancer tripartite network, we predicting potential 
drugs for breast cancer. If a drug and breast cancer have common miRNA neighbors, 
there will be a connection between them. Finally, there are 25 common miRNAs 
between drugs and breast cancer. We use formula (3) to calculate the average distance 
between the 25 miRNAs related to breast cancer and drugs as the drug-breast cancer 
relationship distance score, ,A Bd . 
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Where , 'iA Bd  represents the distance between the i -th miRNA of disease A and the 
drug B ; n represents the number of miRNAs corresponding to disease A . Here, A = 
breast cancer and n = 25. 
In order to make the drug-disease distances be proportional to their direct correlations, 
we use formula (4) to normalize ,A Bd  as ,A BS : 
,
,
d A B
A B
d d
Max d
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Max Min
                              (4) 
Where dMax  and dMin  represent the maximum and the minimum of all the 
drug-disease distances, respectively; ,A Bd represents the distance between disease A 
and drug B; ,A BS  represents the direct association between disease A and drug B. 
 Results 
CTD benchmark verification  
In our study, we choose breast cancer as case, the drug-breast cancer associations are 
ranked in descending order according to their scores. In order to verify the accuracy 
of our results, we use the drug-breast cancer relationships data in Comparative 
Toxicogenomics Database (CTD)34 as benchmark. As shown in Figure 3, we give the 
precision curves of predicted drug-breast cancer relationship results. For each given 
threshold, the precision of our method is calculated by formula (5). 
= CTDPprecision
P
                               (5) 
Where P  represents the number of predicted drug-disease pairs; CTDP  represents 
the number of drug-disease pairs, which can be found in CTD database. 
In Figure 3, we give the precision curves of predicted drug-breast cancer pairs at 
different top-x%. From the figure, we find the higher the associations ranking, the 
higher the accuracy. Hence, for the breast cancer, we choose top 30 drugs for further 
analysis. The top 30 drugs related to breast cancer are shown in Table 2. We validate 
the 30 drugs by CTD database and find 11 (36.7%) of them are marked as 
“therapeutic (T)”, which means that they have a highly correlation with breast cancer. 
In addition, we find 14 of the rest 19 drugs also have connections with breast cancer 
in CTD database with inference score over 0 and they are marked as “Ref” in Table 2. 
That is to say, there are 83.3% (25/30) drugs can be found in the CTD database and 
we predict five potential drugs for breast cancer (DB08871, DB00031, DB08813, 
DB08896, and DB06813, marked as boldface in Table 2). 
 Figure 3. The precision of our predictions at different top-x% drug-breast cancer pairs.  
Clinical evaluation 
For the five predicted drugs, we further analyze them based on the ClinicalTrials.gov 
(https://clinicaltrials.gov/). ClinicalTrials.gov is a registry and results database of 
publicly and privately supported clinical studies of human participants conducted 
around the world. Currently, it lists 242,537 studies with locations in all 50 states and 
in 198 countries (April 25, 2017). From the ClinicalTrials.gov, we can find 84 records 
for drug Eribulin mesylate (DB08871) treat breast cancer. For example, “Eribulin 
Mesylate Phase IV Clinical Trial in Korean Patients with Metastatic or Locally 
Advanced Breast Cancer (ESKIMO) (NCT01961544)”, the purpose is assessing the  
safety of Eribulin which is approved for the treatment of the patients in Korea with 
locally advanced or metastatic breast cancer; “Eribulin with Trastuzumab as First-line 
Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer  
 Table 2. The top 30 drugs related to breast cancer  
Rank Drugbank ID Drug name Marker Inference Score Similarity Score
1 DB08818 Hyaluronic acid Ref 61.1 1.00000 
2 DB00570 Vinblastine T 40.6 0.97977 
3 DB00642 Pemetrexed T 12.38 0.97666 
4 DB01169 Arsenic trioxide T 212.32 0.96998 
5 DB00242 Cladribine Ref 14.83 0.96343 
6 DB04967 Lucanthone Ref 45.07 0.96120 
7 DB09073 Palbociclib T 53.75 0.96083 
8 DB02701 Nicotinamide Ref 63.26 0.96013 
9 DB01005 Hydroxyurea Ref 32.57 0.95909 
10 DB01204 Mitoxantrone T 25.1 0.95847 
11 DB00309 Vindesine sulfate T 2.54 0.95388 
12 DB00361 Vinorelbine T 4.36 0.95388 
13 DB08871 Eribulin None None 0.95388 
14 DB01394 Colchicine Ref 50.29 0.95213 
15 DB01229 Paclitaxel T 111.41 0.95050 
16 DB01248 Docetaxel T 72.35 0.95050 
17 DB00440 Trimethoprim Ref 6.82 0.94971 
18 DB01179 Podofilox Ref 2.87 0.94918 
19 DB05260 Gallium nitrate Ref 19.88 0.94671 
20 DB00441 Gemcitabine T 112.67 0.94582 
21 DB00031 Tenecteplase None None 0.94357 
22 DB08813 Nadroparin None None 0.94325 
23 DB00432 Trifluridine Ref 12.49 0.94205 
24 DB01073 Fludarabine Ref 59.43 0.94184 
25 DB00694 Daunorubicin Ref 85.05 0.94044 
26 DB00970 Dactinomycin Ref 98.94 0.93988 
27 DB08896 Regorafenib None None 0.93853 
28 DB06813 Pralatrexate None None 0.93853 
29 DB00563 Methotrexate T 123.36 0.93799 
30 DB00615 Rifabutin Ref 2.89 0.93433 
Ranked by drug-breast cancer similarity score. Marker has three values: T(therapeutic), Ref (inferred by genes) and None (no 
record in CTD database). Inference Score represents the score for the inference based on the topology of the network consisting 
of the chemical, disease, and one or more genes used to make the inference.  
(NCT01269346)”, the purpose is evaluating the safety and efficacy of Eribulin 
mesylate in combination with trastuzumab as first line treatment in female subjects 
with locally recurrent or metastatic human epidermal growth factor receptor (HER2) 
positive breast cancer; “Eribulin Mesylate in Treating Patients with Previously 
Treated Metastatic Breast Cancer (NCT01908101)”, and so on. For drug Nadroparin 
(DB08813), we find one record: “Prevention of Venous and Arterial 
 Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low 
Molecular Weight Heparin (Nadroparin Calcium) (NCT00951574)”, 1200 patients 
with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head 
and neck cancer undergoing chemotherapy will be randomly assigned in a 2:1 ratio 
and in double-blind conditions to a treatment with subcutaneous low molecular 
weight heparin (nadroparin calcium, one injection/day) or placebo for the overall 
duration of chemotherapy or up to a maximum of 4 months. For drug Regorafenib 
(DB08896), we find three records related with breast cancer, “Refametinib in 
Combination with Regorafenib in Patients with Advanced or Metastatic Cancer 
(NCT02168777)”, “Effect of Regorafenib on Digoxin and Rosuvastatin in Patients 
with Advanced Solid Malignant Tumors (NCT02106845)”, and so on. For drug 
Pralatrexate (DB06813), we find a clinical study of Pralatrexate in 22 female patients 
with previously-treated breast cancer (NCT01118624). Only one drug, Tenecteplase 
(DB00031) was not found in ClinicalTrials.gov. 
Literature curation 
In the above section, the top 30 drugs related with breast cancer are validated by CTD 
database and Clinical database. After our analysis, we obtain five potential drugs 
(Eribulin mesylate, Tenecteplase, Nadroparin, Regorafenib, Pralatrexate) for breast 
cancer. In ClinicalTrials.gov database, only one drug, Tenecteplase, cannot be found 
its corresponding record. In this section, we will analyze the five potential drugs for 
breast cancer by literature mining. 
 Eribulin mesylate (DB08871) is an anticancer drug marketed by Eisai Co. under the 
trade name Halaven, which was approved by the U.S. Food and Drug Administration 
(FDA) on November 15, 2010, to treat patients with metastatic breast cancer35. In 
2016, Kurebayashi J et al. investigated the combined effects of Eribulin and 
antiestrogens. They used a panel of eight breast cancer cell lines, including five 
estrogen receptors (ER)-positive and three ER-negative cell lines. The results of this 
study demonstrate that Eribulin had potent antitumor effects on estrogen-stimulated 
ER-positive breast cancer cells36. 
Nadroparin (DB08813) is an anticoagulant belonging to a class of drugs called low 
molecular weight heparins (LMWHs), which is used in general and orthopedic 
surgery to prevent thromboembolic disorders. In 2015, Sun Y et al.37 used the MTT 
test to observe the effect of different concentrations of nadroparin on the growth 
capacity of breast cancer cells MDA-MB-231. The purpose was to study the effect of 
nadroparin in the migration of breast cancer cells MDA-MB-231 and its action 
mechanism. The results show that nadroparin can inhibit the growth capacity of breast 
cancer cells MDA-MB-231 and the migration and invasion of breast cancer cells 
MDA-MB-231. Its mechanism is to down-regulate MMP-2 and MMP-9 expressions 
after combining with Integrin β3. 
Regorafenib (DB08896) is an oral multi-kinase inhibitor developed by Bayer which 
targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). 
Regorafenib has been demonstrated to increase the overall survival of patients with 
metastatic colorectal cancer38. Stalker L et al. using regorafenib in mammary tumor 
 cell lines, the results show regorafenib may prove clinically useful in inhibiting breast 
cancer cell migration and metastasis39. Su J C et al. investigated the potential of 
regorafenib to suppress metastasis of triple-negative breast cancer (TNBC) cells 
through targeting SHP-1/p-STAT3/VEGF-A axis and found a significant correlation 
between cancer cell migration and SHP-1/p-STAT3/VEGF-A expression in human 
TNBC cells40. 
Pralatrexate (DB06813) is an anti-cancer drug. It is the first drug approved as a 
treatment for patients with relapsed T-cell lymphoma 41 . Pralatrexate results in 
increased activity of CASP3 protein, which has been found to be necessary for normal 
brain development as well as its typical role in apoptosis, where it is responsible for 
chromatin condensation and DNA fragmentation42.  
Tenecteplase (DB00031) is a tissue plasminogen activator (tPA) produced by 
recombinant DNA technology using an established mammalian cell line and used as a 
thrombolytic drug. Nielsen VG et al.43 to study whether tissue-type plasminogen 
activator (tPA) in plasma obtained from patients with breast cancer, lung cancer, 
pancreatic cancer and colon cancer is less than that obtained from normal individuals. 
The results show that tissue-type plasminogen activator-induced fibrinolysis in breast 
cancer, lung cancer, pancreatic cancer and colon cancer patients is enhanced. 
Sumiyoshi K et al.44 found that the increase in levels of plasminogen activator and 
type-1 plasminogen activator inhibitor in human breast cancer may play a role in 
tumor progression and metastasis. Although we have not found the relationship 
between tenecteplase (DB00031) and breast cancer through the literatures, the drug 
 had the similar effects as nadroparin45. Therefore, we infer that tenecteplase is likely 
to have effect on breast cancer. 
KEGG pathway functional enrichment analysis  
In this section, we will further make KEGG pathway enrichment analysis on five 
potential drugs and their associated disease. KEGG (http://www.kegg.jp/ or 
http://www.genome.jp/kegg/) is an encyclopedia of genes and genomes46. Its primary 
goal is to assign functional meanings to genes and genomes both at the molecular and 
higher levels. Thus, drugs or diseases can be associated with certain pathways through 
their related genes. If a drug has overlapping KEGG pathways with a disease, the drug 
and the disease may have great relevance. That is, the drug may treat or cause the 
disease by acting on the overlapping pathways.  
We use DAVID47 , 48  functional annotation tool for KEGG pathway enrichment 
analysis. DAVID provides a comprehensive set of functional annotation tools for 
investigators to understand biological significance of a large number of genes. For 
any given gene list, DAVID is able to visualize genes on BioCarta & KEGG pathway 
maps, identify enriched biological themes, especially GO terms, and so on. Therefore, 
we use DAVID to identify overlapping KEGG pathways between potential drugs and 
breast cancer. The p-value is set to be less than 0.05.  
We find Nadroparin and Regorafenib have 4 and 15 overlapping KEGG pathways 
with breast cancer, respectively. The details are shown in Table 3. From Table 3, we 
can find their corresponding p-values are very small.  
 Although the drug Eribulin mesylate has not overlapping functional pathways with 
the breast cancer at present, it can be enriched to “hsa04540: Gap junction”. In fact, 
protein connexin 43 (Cx43), a part of intercellular gap junctions, is frequently 
down-regulated in tumors49. Studies have demonstrated that gap junctions (GJs) 
composed of connexin (Cx) proteins have the potential to modulate drug 
chemosensitivity in multiple tumor cells50.  
Table 3. Overlapping KEGG pathways between potential drugs and breast cancer  
Drug Name Overlapping enriched pathways p-value 
Nadroparin 
hsa05210: Colorectal cancer 
hsa05161: Hepatitis B 
hsa05166: HTLV-I infection 
hsa05200: Pathways in cancer 
0.00897 
0.02098 
0.03704 
0.04687 
Regorafenib 
hsa04015: Rap1 signaling pathway 
hsa04014: Ras signaling pathway 
hsa04151: PI3K-Akt signaling pathway 
hsa05230: Central carbon metabolism in cancer 
hsa05215: Prostate cancer 
hsa05200: Pathways in cancer 
hsa05218: Melanoma 
hsa05214: Glioma 
hsa05221: Acute myeloid leukemia 
hsa05205: Proteoglycans in cancer 
hsa05220: Chronic myeloid leukemia 
hsa04012: ErbB signaling pathway 
hsa05206: MicroRNAs in cancer 
hsa05231: Choline metabolism in cancer 
hsa04722: Neurotrophin signaling pathway 
3.41E-14 
7.18E-14 
3.36E-10 
4.38E-08 
2.21E-07 
1.13E-06 
4.76E-06 
1.65E-04 
0.00404 
0.00433 
0.00660 
0.00952 
0.01157 
0.01269 
0.01761 
For drug Tenecteplase, we find one function enrichment pathway: “hsa04610: 
Complement and coagulation cascades”. In 2016, based on the microarray data of 
GSE3467 from Gene Expression Omnibus(GEO) database, Yu J et al.51 identified the 
differentially expressed genes (DEGs) between 9 PTC samples and 9 normal controls. 
The purpose was predicted key genes and pathways in papillary thyroid carcinoma. 
 Their results showed that the highly expressed genes in papillary thyroid carcinoma 
were mainly enriched on the “hsa04610: Complement and coagulation cascades” 
functional pathway. As for Pralatrexate, because it has only two targets: DHFR and 
TYMS, it has few related KEGG pathways. That is the main reason that Pralatrexate 
has no overlapping KEGG pathways with breast cancer at present. 
Overlapping genes between enriched KEGG pathways 
To further analyze our results, for Eribulin mesylate, Tenecteplase and Pralatrexate, 
we calculate the common genes between enriched pathways of each drug and those of 
breast cancer. The more common genes, the stronger relationship between the drug 
and disease. The results are shown in Figure 4A-C, respectively. The purple hexagon 
nodes represent the enriched pathways of a drug. The light green circular nodes 
represent breast cancer enriched pathways. The width of edges represents the number 
of common genes between two pathway sets. The wider the edge, the more the 
number of common genes. From Figure 4, we can find the three drugs Eribulin 
mesylate, Tenecteplase and Pralatrexate all have strong connection with breast cancer, 
which further imply the three drugs are likely to be the potential treatments of breast 
cancer. 
  
A 
 
B 
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Figure 4. The common genes between enriched pathway sets of drugs and breast cancer. The purple 
hexagon nodes represent the enriched pathways of a drug. The light green circular nodes represent 
breast cancer enriched pathways. The width of edges represents the number of common genes between 
two pathway sets. The wider the edge, the more the number of common genes. (A) The common genes 
between enriched pathway sets of Eribulin mesylate and breast cancer. (B) The common genes between 
enriched pathway sets of Tenecteplase and breast cancer. (C) The common genes between enriched 
pathway sets of Pralatrexate and breast cancer. 
Discussions and conclusions  
At present, “undruggable” proteins can be targeted via their miRNA gene regulators, 
enabling the treatment of diseases that seem impossible to cure. Human diseases 
result from the disordered interplay of tissue- and cell lineage–specific processes. 
Therefore, here we propose a new method miTS to predict new indications of drugs 
based on miRNA data and the tissue specificities of diseases. Taking breast cancer as 
case study, we predict five potential drugs and analyze them from five aspects: CTD 
benchmark, clinical records, literature curation, KEGG pathway functional 
enrichment analysis and overlapping genes between enriched KEGG pathways. We 
find for the five new drugs, they are supported at least in three ways. In particular, 
Regorafenib (DB08896) has 15 overlapping KEGG pathways with breast cancer and 
 their p-values are all very small. In addition, whether in the literature curation or 
clinical validation, Regorafenib has a strong correlation with breast cancer. All the 
evidence shows Regorafenib is likely to be a truly effective drug, worthy of our 
further study. The results have demonstrated the performance of our model and the 
feasibility of drug repositioning based on miRNA data and tissue specificity.  
Due to the incompleteness of data, there may be some biases in our method. With the 
continuous improvement of data, our method miTS will find more effective drugs for 
disease treatment. All in all, our research reveals a promising perspective to predict 
drug-disease relationships and seeks new opportunities for drug repositioning.  
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